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individuals, but also on both alleles 
in another unaffected individual in 
the same family. Beyond proving 
KRT14pA413T to be a nonpathogenic 
polymorphism, at least in the Asian 
population, it is intriguing to specu­
late as to why this sequence variant 
has persisted in the Asian population. 
One possibility is that the alanine­to­
threonine alteration is advantageous. 
In fact, Natsuga et al. noted less 
keratin filament aggregation in the 
HaCaT cells transfected with KRT14 
A413T than in the wild­type cells (6% 
vs. 13%, respectively), suggesting that 
there might even be a protective effect 
of having this sequence variant. The 
KRT14pA413P keratinocytes had 49% 
keratin bundling, but the possibil­
ity that the combination of the A413P 
and A413T, as existed clinically in 
the uncle, led to less keratin aggre­
gation was not tested. In addition, 
this uncle was said to be “no worse” 
than the much younger proband, but 
the authors did not report whether his 
disease was less severe, especially 
when he had been the same age as the 
proband, given the tendency toward 
improvement in EBS with advancing 
age in many patients.
The techniques used by Natsuga et 
al. to unravel the yin and yang of the 
various alterations in keratin genes and 
their impact on skin integrity could well 
be applied to address the question of 
whether KRT14pA413T might improve 
keratin stability. Furthermore, these 
types of studies should be extended 
to evaluate the impact of polymorphic 
changes in the many keratin genes that 
impact skin beyond keratins 5 and 14.
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Interpretation of Skindex-29 Scores
Francesca Sampogna1 and Damiano Abeni1
In this Commentary, we compare two categorizations of a dermatological 
health–related quality-of-life (HRQoL) instrument, the Skindex-29. One was cre-
ated on the basis of an anchor-based method, the other on a distribution-based 
method. Differences between the two classifications are discussed, emphasizing 
the importance of the interpretability of HRQoL measures.
Journal of Investigative Dermatology (2011) 131, 1790–1792. doi:10.1038/jid.2011.191
One essential property of a measure­
ment instrument is the interpretabil­
ity of its data. An understanding of the 
meaningfulness of a result is necessary 
for physicians in choosing treatments; 
for patients in understanding their con­
ditions and their changes over time; 
and for policy makers in evaluating 
relationships among benefits, adverse 
effects, and cost. In the field of health­
related quality of life (HRQoL), the 
problem of establishing meaningfulness 
is especially challenging (Guyatt et al., 
2002). Although we easily understand, 
for example, the significance of an 
increase or a decrease of one degree 
Fahrenheit or Celsius in body tempera­
ture, it is not clear how to interpret a 
five­point change in a HRQoL scale 
measurement. In this issue, Prinsen et 
al. report scores for mildly, moderately, 
and severely impaired HRQoL for the 
three subscales—emotions, symptoms, 
and functioning—of the Skindex­29 
(Chren et al., 1997). This study com­
pletes a previous study (Prinsen et al., 
2010), in which the authors identified 
cutoff points only for severely impaired 
HRQoL. To identify the categories, the 
authors used an anchor­based method 
(Lydick and Epstein, 1993) that consists 
of comparing measures of HRQoL with 
other measures or phenomena that have 
relevance to patients. In particular, they 
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used a cross­sectional method based on 
patients’ ratings of their HRQoL.
The categorization of the Skindex­29 
was previously proposed by Nijsten 
et al. (2009), using mixture analysis (a 
distribution­based method) to obtain 
cutoff scores (Bohning et al., 1998). This 
analysis assesses whether a distribution 
of a variable consists of different over­
lapping but independent “subdistribu­
tions” and categorizes the observations 
in different mixture components using 
posterior probabilities.
The categories obtained with the two 
approaches differ in several respects. 
In Table 1 we compare the categoriza­
tion of data from studies performed by 
our group (and not previously used in 
the mixture analysis) using both sets 
of cutoffs. The first of each pair of col­
umns, labeled “Psoriasis IMPROVE,” 
refers to data from the IMPROVE study 
of in­patients with psoriasis (Sampogna 
et al., 2006); the second of each pair, 
labeled “Survey 2010,” refers to data 
from a survey of more than 2,500 out­
patients with various dermatological 
conditions (Tabolli et al., 2011). Mild or 
very mild HRQoL impairment, although 
reported in separate groups by Nijsten 
et al. (2009), are presented together 
by Prinsen et al. (2011, this issue). The 
discrepancies in the results are quite 
evident when dealing with a sample of 
all dermatological conditions (“Survey 
2010”), several of which seldom highly 
impair patients’ HRQoL. Thus, in the 
Prinsen distribution the first category 
includes most cases. In addition, the 
range of some of the Prinsen classes is 
very narrow, so only a small percentage 
of patients fall into such categories. On 
the other hand, some Nijsten catego­
ries include a wide range of scores (the 
“mild” class of the emotions scale and 
the “moderate” class of the functioning 
scale, for example).
Our aim here is not to judge the cor­
rectness of the proposed classifications 
but to show how different methods may 
lead to different results. Both categori­
zations are valid and built according 
to well­established methods, but they 
may not represent the final say. In fact, 
to focus on a single example, it is diffi­
cult to reconcile results as discrepant as 
those seen for the symptoms scale in a 
sample of patients hospitalized for pso­
riasis. In this example, the upper limit of 
the “mild” category in the Prinsen clas­
sification is well above the lower limit 
of the “severe” category in the Nijsten 
classification; therefore, different deci­
sions would be made if these categories 
were used to decide a patient’s eligibil­
ity for systemic treatment. If “moderate 
to severe symptoms” was the criterion 
for systemic treatment in patients with 
psoriasis, 31.5% of patients hospital­
ized and followed in the IMPROVE 
study would not have been eligible 
according to the Prinsen categoriza­
tion, compared with 6.7% according 
to Nijsten. Looking at a specific disease 
such as alopecia areata in the “Survey 
2010” study, large discrepancies were 
observed (data not shown). For exam­
ple, patients were classified with a mild 
HRQoL impairment in the functioning 
scale in 75.5% (Prinsen) versus 50.9% 
(Nijsten) of cases; similarly, patients 
were classified with a severe impact 
on emotions in 32.1% (Prinsen) versus 
13.2% (Nijsten) of cases.
table 1. Percentages of a sample of 936 patients hospitalized with psoriasis (Sampogna et al., 2006) and a 
sample of 2,576 consecutive outpatients with various dermatological conditions (tabolli et al., 2011) according 
to the categorization of Skindex-29 by Prinsen et al. and nijsten et al.
emotions Psoriasis  
ImProVe (%)
Survey 
2010 (%)
Symptoms Psoriasis 
ImProVe (%)
Survey 
2010 (%)
Functioning Psoriasis  
ImProVe (%)
Survey 
2010 (%)
Cutoff—Prinsen
Mild
0–23.9
16.4 53.3
Mild
0–38.9
31.5 65.8
Mild
0–20.9
31.3 73.2
Moderate
24–34.9
15.2 13.6
Moderate
39–41.9
4.2 4.0
Moderate
21–31.9
15.5 9.7
Severe
35–38.9
7.8 5.8
Severe
42–51.9
17.1 11.4
Severe
32–36.9
4.7 2.6
Very severe
39+
60.6 27.3
Very severe
52+
47.2 18.8
Very severe
37+
48.5 14.5
Cutoff—Nijsten
Very little
0–5.9
1.8 19.3
Very little
0–3.9
2.2 25.3
Very little
0–3.9
6.5 37.3
Mild
6–24.9
14.6 34.0
Mild
4–10.9
4.5 9.7
Mild
4–10.9
11.1 21.5
Moderate
25–49.9
37.0 30.1
Moderate
11–25.9
10.6 18.4
Moderate
11–32.9
29.2 24.1
Severe
50+
46.6 16.6
Severe
26–49.9
29.3 23.5
Severe
33+
53.2 17.1
Extremely severe
50+
53.4 23.1
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There is considerable debate over the 
advantages and disadvantages of anchor­
based and distribution­based methods 
(Crosby et al., 2003; Testa, 2000). 
Distribution­based approaches are 
based on the statistical characteristics of 
the sample and thus are sensitive to the 
homogeneity of the distribution of the 
sample from which they are derived. 
Anchor­based methods, which are 
based on patients’ ratings, are thought to 
provide the best measure of the signifi­
cance of change from the individual’s 
perspective. However, anchor­based 
methods rely on global ratings, may 
vary on the basis of whether those 
anchors are collected prospectively or 
retrospectively, and may account for 
some of the variance in HRQoL scores. 
In addition, these methods rely heav­
ily on the representativeness of the nor­
mative sample; this is even more true 
of anchor­based methods because the 
anchor points are often also dependent 
on subjective choices and sociocultural 
environments. In other words, how use­
ful are such results when applied to sets 
of patients with a different case mix, in 
terms of both relative proportions of dif­
ferent skin conditions and clinical sever­
ity of disease within each condition?
Norman et al. (2001) conducted a 
simulation comparing the two methods 
and reported equivalent information, 
Clinical Implications
•  “Categories of quality-of-life impairment” are necessary for applying 
quality-of-life data in clinical settings.
•  Differences in methods of categorization and normative samples may 
yield different results.
•  The usefulness of a given set of categories of quality-of-life impairment 
must be judged by the performance of such categories in the field.
whereas Koloktin et al. (2002) reported 
comparable values for anchor­based 
and distribution­based methods in obe­
sity­specific quality of life at moderate 
levels of impairment but markedly dif­
ferent values for those with severe and 
mild impairments.
The debate is far from its conclusion. 
As suggested by Crosby et al. (2003), it 
would be useful to integrate information 
from the two approaches as some stud­
ies have attempted to do (Jacobson and 
Truax, 1991). In dermatology, it would be 
desirable to conduct analyses using both 
methods of categorization, provided that 
representative samples of the population 
with skin conditions are available.
In any case, it is important to consider 
that a measurement instrument will be 
most useful when it is possible to inter­
pret its results. And judgments about the 
usefulness of interpretive tools such as 
a given set of “categories of quality of 
life” will ultimately be based on the per­
formance of such tools in the field, in 
daily clinical routines, and for different 
patient populations.
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